posted on 2023-04-04, 01:25authored byLisa M. Maurer, Jessica D. Daley, Elina Mukherjee, Rosemarie E. Venier, Claire M. Julian, Nathanael G. Bailey, Michelle F. Jacobs, Chandan Kumar-Sinha, Haley Raphael, Nivitha Periyapatna, Kurt Weiss, Katherine A. Janeway, Rajen Mody, Peter C. Lucas, Linda M. McAllister-Lucas, Kelly M. Bailey
Benign germline BARD1 variants.
Funding
Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)
현대자동차그룹 | Hyundai Motor America | Hyundai Hope On Wheels (Hope On Wheels)
HHS | NIH | National Cancer Institute (NCI)
HHS | National Institutes of Health (NIH)
Burroughs Wellcome Fund (BWF)
History
ARTICLE ABSTRACT
This work provides preclinical support for the inclusion of pediatric patients with advanced Ewing sarcoma and pathogenic germline variants in BARD1 in future clinical trials testing novel agents inducing DNA damage/targeting DNA damage repair.